SG Americas Securities’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-29,601
| Closed | -$1.19M | – | 3356 |
|
|
2026
Q1 | $1.19M | Sell |
29,601
-537,445
| -95% | -$11.6M | ﹤0.01% | 1653 |
|
|
2025
Q4 | $14.2M | Buy |
567,046
+149,654
| +36% | +$3.51M | 0.02% | 624 |
|
|
2025
Q3 | $9.45M | Buy |
417,392
+372,289
| +825% | +$8.68M | 0.03% | 339 |
|
|
2025
Q2 | $781K | Sell |
45,103
-321,041
| -88% | -$5.94M | ﹤0.01% | 1333 |
|
|
2025
Q1 | $8.01M | Buy |
366,144
+313,743
| +599% | +$8.67M | 0.03% | 358 |
|
|
2024
Q4 | $1.67M | Buy |
52,401
+28,932
| +123% | +$870K | 0.01% | 653 |
|
|
2024
Q3 | $677K | Sell |
23,469
-84,092
| -78% | -$3.11M | ﹤0.01% | 1424 |
|
|
2024
Q2 | $4.13M | Buy |
107,561
+60,026
| +126% | +$2.72M | 0.02% | 637 |
|
|
2024
Q1 | $2.79M | Sell |
47,535
-1,366
| -3% | -$87.1K | 0.01% | 748 |
|
|
2023
Q4 | $2.93M | Sell |
48,901
-125,668
| -72% | -$6.37M | 0.03% | 515 |
|
|
2023
Q3 | $6.64M | Buy |
174,569
+73,458
| +73% | +$3.23M | 0.08% | 231 |
|
|
2023
Q2 | $9.21M | Buy |
101,111
+90,048
| +814% | +$7.77M | 0.07% | 188 |
|
|
2023
Q1 | $730K | Sell |
11,063
-20,319
| -65% | -$1.17M | 0.01% | 1408 |
|
|
2022
Q4 | $1.62M | Buy |
31,382
+3,520
| +13% | +$187K | 0.02% | 656 |
|
|
2022
Q3 | $1.9M | Sell |
27,862
-23,894
| -46% | -$1.41M | 0.02% | 610 |
|
|
2022
Q2 | $2.34M | Buy |
51,756
+47,611
| +1,149% | +$2.17M | 0.02% | 657 |
|
|
2022
Q1 | $211K | Sell |
4,145
-173,589
| -98% | -$7.66M | ﹤0.01% | 2397 |
|
|
2021
Q4 | $8.4M | Sell |
177,734
-6,280
| -3% | -$247K | 0.05% | 314 |
|
|
2021
Q3 | $6.07M | Buy |
184,014
+159,061
| +637% | +$8.94M | 0.03% | 451 |
|
|
2021
Q2 | $1.58M | Buy |
24,953
+7,142
| +40% | +$369K | 0.01% | 1271 |
|
|
2021
Q1 | $764K | Buy |
17,811
+15,070
| +550% | +$713K | ﹤0.01% | 1718 |
|
|
2020
Q4 | $157K | Sell |
2,741
-32,198
| -92% | -$1.36M | ﹤0.01% | 2772 |
|
|
2020
Q3 | $1.05M | Buy |
34,939
+30,108
| +623% | +$900K | 0.01% | 1143 |
|
|
2020
Q2 | $158K | Sell |
4,831
-6,696
| -58% | -$215K | ﹤0.01% | 3047 |
|
|
2020
Q1 | $309K | Buy |
11,527
+2,905
| +34% | +$103K | ﹤0.01% | 2207 |
|
|
2019
Q4 | $264K | Sell |
8,622
-57,187
| -87% | -$1.58M | ﹤0.01% | 2280 |
|
|
2019
Q3 | $1.58M | Buy |
+65,809
| New | +$1.81M | 0.01% | 1115 |
|
|
2019
Q2 | – | Sell |
-5,762
| Closed | -$112K | – | 3057 |
|
|
2019
Q1 | $112K | Buy |
+5,762
| New | +$90.6K | ﹤0.01% | 2986 |
|
Other funds holding APLS
SG Americas Securities's APLS Position: Q2 2026 in Review
SG Americas Securities sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 29,601 shares — an estimated $1.19M sold.
SG Americas Securities first reported a position in APLS in Q1 2019 and held it in 28 quarters. The position peaked at $14.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- SG Americas Securities reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- SG Americas Securities sold 29,601 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
- SG Americas Securities first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 28 quarters.
- SG Americas Securities's Apellis Pharmaceuticals position peaked at $14.2M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.